Citations

Clear

13603 citation(s) found for "_, _".

Development and Nested Cross-Validation of Explainable Machine-Learning Models for Predicting the Risk of Propofol-Associated Hypertriglyceridemia in Critically-Ill, Mechanically-Ventilated Patients
Deng, Jiawen , Heybati, Kiyan , Xie, Guohao , Hemang, Y., Deng, J , Xie, G., Poudel, K., Hemang, Y.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A5690-A5690

10.1164/ajrccm.2025.211.abstracts.a5690 Get It

Abstract RATIONALE Propofol is the first-line sedative for critically-ill, mechanically-ventilated patients, but it can increase serum triglyceride levels. Machine-learning (ML) offers a promising approach for individualized risk stratification of propofol-associated hypertriglyceridemia, enabling proactive triglyceride monitoring and sedation optimization. This study aims to develop and validate ML models to predict hypertriglyceridemia risks in critically-ill patients receiving propofol. METHODS We analyzed retrospective data from adult ICU patients on mechanical ventilation receiving continuous propofol infusion for ≥24 hours across four Mayo Clinic sites from May 2018 to June 2023. The primary outcome was hypertriglyceridemia, defined as serum triglycerides >400 mg/dL within 10 days of starting propofol. Ten-fold cross-validation and leave-one-site-out nested cross-validation (LOSO-CV) were used for model tuning and external validation of our modeling process, respectively. Feature selection was conducted through a union of Boruta and least absolute shrinkage and selection operator (LASSO). While COVID status was a strong predictor of hypertriglyceridemia, we concurrently developed non-COVID models to ensure future relevance in non-pandemic settings. Six ML algorithms (logistic regression, support vector machines, random forests, LightGBM, XGBoost, and multilayer perceptrons) were tuned using Bayesian optimization to minimize cross-entropy loss. Classification thresholds were set to target sensitivity ≥80%. Model performance was evaluated using AUC-ROC, Brier score, sensitivity, and specificity. Models with the highest Youden's Index were designated the best-performing model. Model explainability was assessed using permutation importance and SHapley Additive exPlanations (SHAP). RESULTS We included 3922 eligible patients with triglyceride measurements. Of these, 3042 patients were COVID-negative and used for non-COVID modeling. The best-performing non-COVID models achieved an average AUC-ROC of 0.69 (95% confidence interval [CI] 0.68-0.70), Brier score of 0.12 (95% CI 0.09-0.14), sensitivity of 0.79 (95% CI 0.75-0.83), and specificity of 0.48 (95% CI 0.44-0.52) during LOSO-CV. The best-performing models that included COVID status achieved an average AUC-ROC of 0.71 (95% CI 0.70-0.72), Brier score of 0.13 (95% CI 0.10-0.16), sensitivity of 0.78 (95% CI 0.71-0.84), and specificity of 0.51 (95% CI 0.45 to 0.56) during LOSO-CV. The permutation importance results of the final non-COVID model are shown in the figure. CONCLUSION We have developed sensitive ML models for predicting hypertriglyceridemia risks in critically-ill patients receiving propofol. Although developed during the COVID-19 pandemic, the non-COVID models are more likely to have future relevance, and they have similar performance as models including COVID status. These models will be integrated into a web-based clinical calculator and undergo further validation in prospective studies.
Causes of Death in US Adults With a COPD Diagnosis, An Analysis of the US National Vital Statistics System
Scrodin, M. Dulohery, Harris, B.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A5324-A5324

10.1164/ajrccm.2025.211.abstracts.a5324 Get It

Abstract Introduction: Chronic obstructive pulmonary disease (COPD) is a top 5 cause of death and bears significant morbidity and mortality. The role of multimorbidity in patients with COPD has been shown to affect quality of life, increase risk of disease exacerbation, and mortality. COPD-targeted treatments have shown limited effects on mortality, but this patient population may benefit from practitioners more aggressively managing other comorbid conditions. Understanding which diseases have the largest impact on mortality in COPD patients may help providers understand which comorbidities to manage aggressively. Methods: We used the National Vital Statistics System (NVSS; 2019 data release), which collects all death certificate data for US citizens along with basic demographic information. We only included those who died with COPD as a diagnosis on their death certificate, defined as those who had international classification of disease, version 10 (ICD-10) codes J40-J44. We then dichotomized the causes of death by COPD vs non-COPD causes, based on the underlying cause of death (UCOD) on the death certificate. UCOD is defined by the NVSS as “the disease or injury which initiated the train of events leading directly to death.” Demographic information was collected, race was self-reported, and level of education was dichotomized as less than HS diploma vs higher. We used chi-square or t-test to determine statistical significance (defined as p <0.05) between groups for demographic information. Results: 308,856 US adults had an ICD-10 code associated with COPD written on their death certificate, of these 156,499 (50.6%) had a UCOD other than COPD. Overall, mean age 77.1 years (SD 2.6 years), 49% were female. The 10 most common diagnoses of those who died of non-COPD causes are presented in Figure 1, with the three most common causes being lung cancer (23689, 15.1%), atherosclerotic heart disease (22,848, 14.6%), and acute myocardial infarction (6422, 4.1%). Six of the top 10 are cardiovascular diseases. Conclusion: Patients with COPD are at high risk of mortality from comorbid conditions, with around 50% dying from non-COPD etiologies according to death certificate data. Most of these etiologies have evidence-based and mortality-reducing interventions such as lung cancer screening and management of cardiovascular risk factors including cholesterol-lowering medications and antihypertensives. While we don't have more granular data in terms of medications and therapies, these findings suggest that guideline-oriented approaches, both in terms of lung cancer screening and cardiovascular-risk reduction, may have a strong impact on mortality reduction in this patient population.
New Onset Atrial Fibrillation in Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnea, and Overlap Syndrome: A Retrospective Observational Study from the Trinetx Database
Hoffer, M., Kanaan, Camille, Soin, S., Pham, H.N., Adkins, Arlie , Kanaan, C., Mahmoud, M., Ibrahim, R.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A5315-A5315

10.1164/ajrccm.2025.211.abstracts.a5315 Get It

Abstract RATIONALE:New-onset atrial fibrillation (NOAF) is a common arrhythmia associated with adverse outcomes in patients with chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA). Both conditions, through shared mechanisms, raise the likelihood of NOAF incidence, emphasizing the importance of epidemiological data and preventive measures to prevent NOAF burden. Therefore, we examined the risk of NOAF in patients with COPD, OSA, and their overlap syndrome (OS). METHODS: We extracted data from the Banner Healthcare Organization, US Collaborative Network in TriNetX, identifying three patient cohorts using ICD-10 codes for COPD (J40-J44) and OSA (G47.3). This included 73,540 patients with OS, 198,880 patients with OSA only, and 337,010 patients with COPD only. Patients with a prior diagnosis of AF before their diagnosis of OSA or COPD were excluded. Propensity matching was conducted based on age, sex, ethnicity, and cardiovascular disease risk factors and prevalence including hypertension, tobacco use, dyslipidemia, obesity, and ischemic heart disease. We calculated the relative risk (RR), hazard ratio (HR), and 95% confidence intervals (CI) for incident AF among propensity score-matched cohorts, comparing OS with OSA alone and OS with COPD alone.RESULTS: In the OS vs. OSA only comparison, 63,070 patients were matched per cohort. Lifetime incidence of new AF was higher in the OS group (13.65%) compared to the OSA-only group (8.24%), with an RR of 1.66 [95% CI: 1.60-1.72]. Kaplan-Meier analysis indicated a lower AF-free probability in the OS group (65.96%) than in the OSA-only group (77.03%), with an HR of 1.56 (p < 0.001). In the OS vs. COPD only comparison, 65,810 patients were matched per cohort. Incidence of new AF in the OS group was 13.76%, compared to 9.86% in the COPD-only group, with an RR of 1.40 [95% CI: 1.35-1.44]. Kaplan-Meier analysis showed a lower AF-free probability for the OS group (66.13%) versus the COPD-only group (78.94%), with an HR of 1.28 (p < 0.001). Sensitivity analyses restricted to the first five years post-diagnosis revealed a persistently higher relative risk of incident AF in OS patients, with an RR of 1.67 [95% CI: 1.60-1.73] compared to OSA alone, and an RR of 1.34 [95% CI: 1.29-1.39] compared to COPD alone. CONCLUSION:We identified that patients with OS have a higher risk of NOAF compared to either condition alone. This emphasizes the need for vigilant monitoring and targeted interventions in patients with OS to decrease arrhythmogenicity risks.
Closed Loop, Full Automation of Suspicious Lung Nodule Risk Assessment With AI in Screening Cases
Taha, Abtahir Rahim, Reisenauer, Janani , Kalra, A., Muelly, M. , Reicher, Joshua , Kalra, Angad

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A5226-A5226

10.1164/ajrccm.2025.211.abstracts.a5226 Get It

Abstract RATIONALE: Research since 2017 has highlighted artificial intelligence (AI)-based technologies to assist in detecting and/or classifying lung nodules on Computed Tomography (CT) scans. However, few have combined detection and classification tasks, and most have required extensive hands-on image manipulation to process the cases, which is both costly and time-consuming. Here, we present a closed loop, fully automated software package, Bronchosolve, which handles cases from scan to result without manual intervention. METHODS: The software package combined pre-processing, analysis, and result generation system including a deep learning convolutional neural network (CNN) for assessment of suspicious pulmonary nodules. Model inputs were full CT cases formatted in Digital Imaging and Communications in Medicine (DICOM), without demographics or clinical variables. Automated steps included 1) automatic selection of the optimal CT series for analysis; 2) normalization and pre-processing of the series; 3) AI-based analysis of the images to both detect and classify suspicious lung lesions; and 4) generation of analysis report. The system was trained using a multi-center dataset of over 2,358 cases of suspicious lung nodules, including cancers and non-cancers. A United States-based, multi-site cohort (n=184) was used for initial algorithm validation where positive cases were defined as biopsy-proven cancer within 1 year, and negatives as negative biopsy or 2+ year negative follow-up. RESULTS: In the validation set, the system achieved a technical completion rate of 100%, automatically for all cases. Median patient age was 62.5 years (interquartile range 58.5 to 66.5 years), 45% were former smokers, 55% were current smokers, and 40% were female. The AI cancer risk (CA-risk) model achieved an area under the receiver-operating-characteristic curve (AUC) of 0.828 [CI: 0.773 – 0.883] in differentiating cancer from non-cancer in cases with known suspicious pulmonary nodules, as confirmed by biopsy, surgery, and/or follow-up. These results were statistically superior to Lung-RADS pAUC of 0.669 [CI: 0.601 – 0.737] and trended better than Brock model AUC of 0.783 [CI: 0.723 – 0.842], Figure 1. At the Youden operating point, model sensitivity was 73.1% [CI: 66.7 – 79.5%], and specificity was 82.5% [CI: 77.0 – 88.0%]. The model's performance was consistent across various CT scanner manufacturers and tested slice thickness. CONCLUSIONS: The closed loop, automated software system, Bronchosolve, consistently processed and analyzed a wide range of CT scans, providing accurate assessment in risk-classifying suspicious lung nodules. This approach has the potential to improve non-invasive assessment of lung nodules eliminating the need for additional user training and time.
Aspergillus SP. Positive Airway Samples in People With Non-CF Bronchiectasis is Associated With Higher Biomarkers of Systemic TH2 Inflammation, Allergic Airway Disease, and Airway Co-infection
Poore, T., McShane, Pamela J. , Aksamit, T.R., Richards, C. , Ignatius, Elisa H. , Poore, T. Spencer , Brunton, Amanda E. , Swenson, Colin , Solomon, George M

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3451-A3451

10.1164/ajrccm.2025.211.abstracts.a3451 Get It

Abstract Introduction: Non-Cystic Fibrosis Bronchiectasis (NCFB) is an obstructive pulmonary disease associated with structural lung disease, altered mucociliary clearance, hyper mucus secretion, recurrent infection, and airway inflammation that results in significant morbidity and mortality. Aspergillus sp (Asp) is a common fungi isolated in respiratory specimens of those with lung disease and is associated with both infectious and allergic pulmonary diseases such as Asthma and Cystic Fibrosis. Despite individuals with NCFB having similar phenotypes as these conditions, the impact of Asp on this population is poorly understood. Methods: We performed a cross-sectional retrospective analysis from the US Bronchiectasis and NTM Research Registry (BRR). NCFB patients without a history of lung transplant who had at least one respiratory Asp culture were included. We compared patients with no history of Asp grown from respiratory culture to those with at least one positive respiratory culture for Asp during the available period. Patient demographics, bacterial culture history, lung function, comorbidities, modified Bronchiectasis Severity Index (mBSI), and sputum parameters were analyzed descriptively. Comparisons between groups were conducted using Kruskal-Wallis, independent sample t-tests, and chi-square tests for continuous and categorical variables as appropriate. Results: 3985 people with NCFB met inclusion criteria. 3359 (84.3%) individuals were Asp culture negative compared to 626 (15.7%) individuals with Asp. There were notable differences in race, showing higher proportions of non-Hispanic white (90.4 vs 82.2%) in this population. While the frequency of Chronic Obstructive Pulmonary Disease and Primary Ciliary Dyskinesia were similar, there were more individuals with Asthma (31.3 vs 24.7%, p<0.001) and Allergic Bronchopulmonary Aspergillosis (ABPA) (6.4 vs 2.4%, p<0.001) in the Asp positive group (Figure 1A). The Asp positive group had higher blood eosinophils (150.0 vs 124.0 cells/uL, p=0.026, Figure 1B), had nominally lower lung function (73.5 vs 75.3% ppFEV1, p=0.089), and were more likely to have at least one or more positive bacterial cultures (62.9 vs 51.9%, p<0.001, Figure 1C). There was no significant difference in sex, age, exacerbations, Pseudomonas aeruginosa or NTM positive cultures, sputum volume, or mBSI. Conclusion: Individuals with NCFB and history of one or more positive Asp cultures were more likely to be non-Hispanic white, have a diagnosis of Asthma and/or ABPA, higher blood eosinophils, and more positive airway bacterial cultures. Further work is needed to better understand how Asp contributes to bronchiectasis progression. More expansive analysis and multivariant modeling is underway to better understand the impact of Asp in people with NCFB.
Whole Genome Sequencing Analysis of Severe, Early-onset Chronic Obstructive Pulmonary Disease
Gharib, Salwa, Oelsner, E., Xu, Hanfei , Yu, Bing , Meyers, D.A., Norwood, Arnita F. , Ortega, V.E., Sliwiński, P, Medicine, Trans-Omics in Precision, Silverman, E.K., Cho, M.H. , Oelsner, Elizabeth C. , Oelsner, Elizabeth C , Kim, Katherine Callaway , Hu, X., Chun, Sung , Rasmussen‐Torvik, Laura J. , Sofer, Tamar , Barr, R. Graham , Carson, April P. , Kalhan, Ravi , Kaplan, Robert C. , Lomas, David A. , London, Stephanie J. , Meyers, D.A., O’Connor, George T. , Psaty, Bruce M. , Rich, Stephen S. , Manichaikul, Ani

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3380-A3380

10.1164/ajrccm.2025.211.abstracts.a3380 Get It

Abstract Background:Chronic obstructive pulmonary disease (COPD) is a major global health burden, with genome-wide association studies explaining only a fraction of its heritability. Recent advancements, including large-scale, multi-ancestry whole-genome sequencing and a focus on severe, early-onset cases, offer promising avenues to identify additional COPD-related variants. Furthermore, recent studies show that adjusting for polygenic risk scores (PRS) enhances statistical power to detect rare variants, advancing efforts to understand COPD's genetic basis. Methods:We performed a whole genome sequencing association study of severe, early-onset COPD (FEV1 < 50%, age ≤ 55), FEV1 and FEV1/FVC in eight population-based studies (ARIC, CARDIA, CFS, CHS, FHS, HCHS/SOL, JHS, MESA) and seven COPD-enriched studies (COPDGene, ECLIPSE, Boston Early-Onset COPD Study, LTRC, TCGS (Poland), ICGN, SPIROMICS). We performed single-variant analyses using regenie software, applying a genome-wide significance threshold of P < 5.0 x 10-8. For rare variant set (MAF <1%) analysis, we annotated variants with loss of function or deleterious missense using WGS Annotator and prediction tools LOFTEE, SIFT, and PolyPhen2, then analyzed these variants with SKATO-ACAT method in regenie, adjusting for covariates including sex, sequencing center, and principal components of ancestry. We additionally evaluated adjusting the analyses for PRSs for lung function traits. Results: We analyzed 53,028 participants including 34,751 European, 12,508 African, 1,088 Latino American, and 674 East Asian ancestry. Across cohorts, we analyzed 5,063 severe (FEV1 < 50%) COPD cases, among whom 1,103 were early-onset (age ≤ 55). Excluding variants within 1 Mbp of known variants, single-variant analysis identified 68 novel associations (MAC ≥ 30), with 8 common associations (MAF ≥ 1%) in 6 genomic regions. Our most significant novel association for severe early-onset COPD was rs74297390 (intergenic to POM121L12, MAF = 9.6%, Beta = 0.41, P = 3.5 x 10-8). For FEV1 and FEV1/FVC ratio, variants near DKK2 and AKR1E2 were significantly associated and were replicated in an independent dataset (Shrine et al., 2019). DKK2 is an antagonist in the Wnt pathway. In a preliminary variant set analysis, CHRM3-AS1 was associated with severe early-onset COPD, GPAT with FEV1, and COL8A1I and HMCN1 with FEV1/FVC. With PRS adjustment, ST6GALNAC5 was associated with FEV1/FVC. Conclusions: In a whole genome sequencing study of lung function and severe early-onset COPD, we identified new loci for COPD-related phenotypes, including two novel loci that replicated in an independent dataset. Ongoing work involves variant set-based analyses with additional covariate adjustments, as well as PRS adjustments for binary traits.
Associations Between Recalled Memories of the ICU Stay, Delirium, and Mental Health Outcomes in Critical Illness Survivors at 1-month Follow-up in a Critical Illness Recovery Center
Phan, Emily, Eaton, Tammy L. , Boehm, Leanne M. , Butcher, Brad W. , Danesh, Valerie , McPeake, Joanne , Lindroth, Heidi , Girard, T.D., Potter, Kelly

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3144-A3144

10.1164/ajrccm.2025.211.abstracts.a3144 Get It

Abstract Rationale: Critical illness survivors often experience anxiety, depression, and post-traumatic stress disorder (PTSD) due to traumatic experiences, sedation, and delirium. Early interventions of psychological support may help mitigate mental health deficits post-ICU. Memory of the ICU stay may play a key role in addressing trauma and facilitating therapeutic engagement. Therefore, we sought to determine the relationship between ICU memory recollection, in-ICU delirium, and mental health outcomes at 1-month follow-up in a critical illness recovery center. Methods: We analyzed data collected at 1-month follow-up in a critical illness recovery center seeing adults who had ICU stays of >4 days with sepsis, respiratory failure, and/or delirium. Patients were asked, “Do you remember your experience in the ICU, and if so, can you describe your most impactful memories?” and we qualitatively coded responses for A) presence/absence of memories and B) type of memories described. We analyzed unadjusted associations between demographic, clinical, and mental health measures (anxiety, depression, and PTSD) and memory recollection using chi-square and Wilcoxon rank-sum tests. Results: Among 196 patients seen at 1-month follow-up, 96 (49%) reported memories of their ICU stay. Of these, 44 (46%) described support they received in the ICU (e.g., feeling “safe and watched” by ICU staff, spouse at bedside), 36 (38%) recalled delusions and/or hallucinations (e.g., being kidnapped), 35 (37%) remembered specific treatments (e.g., cardioversion), and 33 (34%) described symptoms (e.g., pain, constipation). Baseline characteristics and critical illness features are shown in the Table. Patients who reported no memories of their ICU stay were more frequently admitted with neurological diagnoses, whereas those who reported memories were more often admitted with trauma or burns (p<0.001). Those without memories had more delirium days than those reporting memories (p=0.02). Although PTSD and anxiety symptoms at 1-month follow-up were not associated with memories, patients who remembered their ICU stay had fewer depression symptoms (p=0.04). Conclusions: One month after their critical illness, half of survivors recalled their ICU experience, with memories ranging from supportive interactions to distressing experiences. In unadjusted analyses, memory recollection was associated with fewer depressive symptoms during follow-up, but a larger study is needed to determine whether this association persists after adjusting for potential confounders. Memories of the ICU may provide a therapeutic foundation for interventions targeting depression after critical illness, such as exposure therapy or ICU diaries, which may improve mental health outcomes in critical illness survivors.
Results From Airflow-3: Randomized, Double Blind, Sham Controlled Study of Targeted Lung Denervation in Patients With COPD
Criner, G.J., Sue, Richard, Ghattas, Christian , Guibert, Nicolas , Valipour, A., Cardenas, José De , Soto, Jose Soto , Slebos, Dirk‐Jan , Bhatt, Surya P. , Strange, Charlie , Degano, Bruno , Eisenmann, Stephan , Marquette, Charles‐Hugo , Sciurba, Frank C. , Shah, Pallav L.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3112-A3112

10.1164/ajrccm.2025.211.abstracts.a3112 Get It

Abstract Rationale: The D'Nerva Targeted Lung Denervation (TLD) System uses radiofrequency energy delivered bronchoscopically to the main bronchi to disrupt parasympathetic nerve innervation to the lung. AIRFLOW-3 clinical trial was a randomized, double blind, sham controlled study to determine the impact of TLD on COPD exacerbations. Methods: AIRFLOW-3 patients had symptomatic COPD (CAT ≥10) with moderate to very severe airflow obstruction (GOLD stage II-IV: 25% ≤ FEV1 ≤ 80% predicted, FEV1/FVC<0.70) and GOLD E status (≥2 moderate or ≥1 severe exacerbation in the prior 12 months) despite optimal medical therapy. The primary endpoint was a time-to-first event comparison of the probability of subjects having a moderate or severe exacerbation, between the Treatment arm (TLD + optimal medical therapy) and the Sham Control arm (optimal medical therapy). Results: 388 patients were randomized 1:1 at 32 clinical sites across the US, EU, and UK. Patients were 67.8 (SD 7.1) years of age, ex-smokers with a 46.7 (22.0) pack-year smoking history, and 41.0 (11.8) post bronchodilator FEV1% pred. SGRQ-C and CAT scores were 62.5 (17.0) and 23.6 (6.3), respectively. Over 90% of patients were on triple therapy (LAMA+LABA+ICS) at baseline and through 1 year of follow up. 42% of patients had prior-year COPD hospitalization(s). There was no difference between groups in the analysis of the primary endpoint. At 1 year, the sham arm exhibited a statistical decline in lung function (decrease in FEV1 and FVC) and worsening of gas trapping (increase in RV). Lung function and gas trapping were stable in the treatment arm. The treatment arm exhibited a statistically significant improvement in dyspnea at one year compared to sham (mMRC, and TDI). These observations led to the identification of a subgroup of TLD treatment responders corresponding to an airway predominant phenotype (lung hyperinflation in the absence of significant emphysema) that demonstrated clinically and statistically significant improvements in lung function and exacerbation frequency and severity (Table). Conclusions: The AIRFLOW-3 clinical trial failed to meet its prespecified primary endpoint. Post-hoc analysis of this robust dataset led to the identification of a responder profile that achieved significant and sustained improvements in lung function, and exacerbation reduction. A future clinical study is being designed to confirm these findings.
Pulmonary Embolism Mortality Trends and Disparities in Patients With Cancer in the United States, 1999 – 2020
Marco, Teresa Navío, Hoffer, Mariëtte J.V. , Ritter, Julia, Sumner, Richard E., Ibrahim, Radwa, Ritter, John , Soin, S., Pham, H.N., Marco, T., Hoffer, M., Sumner, R., Ibrahim, R.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A2842-A2842

10.1164/ajrccm.2025.211.abstracts.a2842 Get It

Abstract RATIONALE: The diagnosis of Pulmonary Embolism (PE) is associated with high mortality and morbidity. In patients with cancer, high-risk pulmonary emboli further escalate these risks. Ensuring access to the necessary resources for appropriate intervention is crucial for improving patient outcomes. However, the resource-intensive nature of managing multiple life-threatening conditions can create barriers for certain demographic populations, leading to disparities in outcomes. To address this issue, we explored mortality trends among diverse groups based on gender, ethnicity, and geographical background in the United States from 1999-2000. METHODS: We obtained mortality data from death certificate queries in the Centers for Disease Control and Prevention Wide-range Online Data for Epidemiologic Research database. Queries included all decedents with the underlying cause of death being PE (I26) in patients with a diagnosis of cancer (C00 – C97). Age-adjusted mortality rates (AAMR) per 100,000 people were compared across demographic populations, and 95% Confidence Intervals were standardized to the year 2000. Log-linear regression models were utilized to assess temporal mortality shifts and calculate annual percentage change (APC) from 1999 to 2020. RESULTS: A total of 179483 PE-related deaths was reported in patients with cancer. The AAMR increased from 2.14 [2.08-2.19] in 1999 to 3.05 [3.00-3.11] in 2020. The cumulative AAMR was 2.42 [2.41-2.43] with an average APC of +1.56% (p<0.001). The mortality rate accelerated following the year 2016, with the years prior having an APC of +0.69%, (p<0.001) and the years following having an APC +5.33% (p<0.001). A higher mortality was observed in males (AAMR 2.71 [2.69-2.73]) than females (2.20 [2.18-2.21]), in rural communities (AAMR 2.50 [2.47-2.53]) compared to urban communities (AAMR 2.38 [2.37-2.40]), and in non-Hispanic (AAMR 2.48 [2.47-2.49]) populations over Hispanic populations (AAMR 1.45 [1.42-1.48]). Mortality was highest in the Black population (AAMR 3.65 [3.60-3.69]), followed by White population (AAMR 2.33 [2.32-2.34]), American Natives (AAMR 1.43 [1.33-1.54]), and Asian (AAMR 1.04 [1.00-1.08]). Geographically, Midwest (AAMR 2.58 [2.56-2.61]) had the highest mortality while the South (AAMR 2.26 [2.24-2.28]) had the lowest mortality. CONCLUSIONS: We identified significant disparities in mortality related to pulmonary embolism (PE) among cancer patients across different demographic populations. Further investigation into these healthcare inequities is essential for addressing the disparities affecting various groups.
Acute Fibrinous and Organizing Pneumonia (AFOP) Demographics, Clinical Presentation, Radiology and Diagnostic Modalities. A Systematic Review of Case Reports
Khan, Ayesha , Khan, Ashraf A. , Lalwani, Anil K. , Platt, Alec B., Yousaf, Zohaib , Khalid, S., Asghar, Muhammad Sohaib

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1820-A1820

10.1164/ajrccm.2025.211.abstracts.a1820 Get It

Abstract Introduction:AFOP is a pattern of lung injury with intra-alveolar fibrin balls and organizing pneumonia. In 2013, the ATS/ERS revised their classification of idiopathic-interstitial-pneumonia to include acute-fibrinous-organizing-pneumonia(AFOP) in their rare histologic patterns. Methods: MEDLINE(PubMed), EMBASE, and Cochrane were searched for AFOP-related case reports/case series. Mesh terms used included (“acute fibrinous and organizing pneumonia” OR AFOP OR “acute fibrinous organizing pneumonia” OR (“acute fibrinous” AND “organizing pneumonia”) OR (“acute fibrinous” AND “organizing pneumonia”). A total of 177 patients were synthesized in these 169 articles, 9 of which were case series and the rest individual case reports. A quality review and data extraction was done on Covidence using a JBI checklist.Results:Mean age of 52.2 +/- 17.4 years with 55% of them were males. The associations were; malignancy (16%), smoking (14%), organ transplant (13%), Hypertension (10%), and use of immunosuppressive agents (6%) were frequent risk factors. Cough (73%), shortness of breath (71%), and fever (61%) were found highly frequent symptoms. Predominant radiological findings were multifocal infiltrates/consolidation (50%) and ground glass appearance (39%). Leukocytosis and inflammatory markers were elevated in most cases. Transbronchial/EBUS (32%), open surgical (29%), imaging-guided (22%), and VATS (14%) were common modes of lung biopsy. Treatment is usually steroids (88%) and antibiotics (69%). Death occurred in 23% of the cases, clinical or radiological improvement was achieved in 69%, while only three recurrences were reported. Most cases are either idiopathic or associated with myelodysplastic syndrome as causative factors reported by authors. DiscussionAFOP presents non-specific symptoms and a community-acquired pneumonia-like clinical picture. Treatment included antibiotics, corticosteroids, and other immunosuppressants with variable outcomes. Discontinuation of suspected drug was the sole treatment strategy reported in some cases. Partial lobectomy/lesion resection was a successful treatment in some instances with localized disease.The survival in AFOP was significantly worse than obliterative bronchiolitis (median time to death 101 vs. 294 days; P = 0.02). A statistically non-significant trend towards higher mortality associated with higher body mass index (BMI) and a long interval between symptom onset and diagnosis of AFOP was reported by Kim et al. in a cohort from South Korea. Conclusion:AFOP being a rare histological pattern of acute lung injury, is a relatively new entity that requires a better clinical and radiologic understanding for the clinical challenge it poses. This systematic review will be able to provide answers to clinicians to think in that direction and manage acute lung injury accordingly.